Tafamidis Cuts Cardiovascular Death and Hospitalization Risk for Up to 90 Months
A post hoc analysis of the ATTR-ACT trial and its long-term extension found continuous tafamidis treatment significantly reduced cardiovascular death ...
A post hoc analysis of the ATTR-ACT trial and its long-term extension found continuous tafamidis treatment significantly reduced cardiovascular death ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine